Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

24432 ARTÍCULOS , VIENDO DEL 22141 AL 22155

Subtypes based on cerebrospinal fluid and magnetic resonance imaging markers in normal elderly predict cognitive decline

Nettiksimmons J, Harvey D, Brewer J, Carmichael O, DeCarli C, Jack CR Jr, Petersen R, Shaw LM, Trojanowski JQ, Weiner MW, Beckett L; Alzheimer's Disease Neuroimaging Initiative.

Neurobiol Aging. 2010 Aug;31(8):1419-28. doi: 10.1016/j.neurobiolaging.2010.04.025. Epub 2010 Jun 9.

Plasma beta-amyloid as potential biomarker of Alzheimer disease: possibility of diagnostic tool for Alzheimer disease

Takeda S, Sato N, Rakugi H, Morishita R.

Mol Biosyst. 2010 Oct;6(10):1760-6. doi: 10.1039/c003148h. Epub 2010 Jun 21.

Alzheimer's Disease Neuroimaging Initiative special issue

Frisoni GB, Weiner MW.

Neurobiol Aging. 2010 Aug;31(8):1259-62. doi: 10.1016/j.neurobiolaging.2010.05.006. Epub 2010 Jun 8.

Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: a longitudinal MRI study

Tosun D, Schuff N, Truran-Sacrey D, Shaw LM, Trojanowski JQ, Aisen P, Peterson R, Weiner MW; Alzheimer's Disease Neuroimaging Initiative.

Neurobiol Aging. 2010 Aug;31(8):1340-54. doi: 10.1016/j.neurobiolaging.2010.04.030. Epub 2010 Jun 8.

Alterations of the sphingolipid pathway in Alzheimer's disease: new biomarkers and treatment targets?

Mielke MM, Lyketsos CG.

Neuromolecular Med. 2010 Dec;12(4):331-40. doi: 10.1007/s12017-010-8121-y. Epub 2010 Jun 23.

FDG-PET for early assessment of Alzheimer's disease: isn't the evidence base large enough?

Lucignani G, Nobili F.

Eur J Nucl Med Mol Imaging. 2010 Aug;37(8):1604-9. doi: 10.1007/s00259-010-1535-9.

Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives

Hampel H, Frank R, Broich K, Teipel SJ, Katz RG, Hardy J, Herholz K, Bokde AL, Jessen F, Hoessler YC, Sanhai WR, Zetterberg H, Woodcock J, Blennow K.

Nat Rev Drug Discov. 2010 Jul;9(7):560-74. doi: 10.1038/nrd3115.

Prediction of MCI to AD conversion, via MRI, CSF biomarkers, and pattern classification

Davatzikos C, Bhatt P, Shaw LM, Batmanghelich KN, Trojanowski JQ.

Neurobiol Aging. 2011 Dec;32(12):2322.e19-27. doi: 10.1016/j.neurobiolaging.2010.05.023. Epub 2010 Jul 1.

Biomarkers of Alzheimer's disease in body fluids

Zheng Y, He J, Hong T.

Sci China Life Sci. 2010 Apr;53(4):490-6. doi: 10.1007/s11427-010-0081-9. Epub 2010 May 7.

Cerebrospinal fluid profile of amyloid β42 (Aβ42), hTau and ubiquitin in North Indian Alzheimer's disease patients

Kandimalla RJ, S P, Bk B, Wani WY, Sharma DR, Grover VK, Bhardwaj N, Jain K, Gill KD.

Neurosci Lett. 2011 Jan 7;487(2):134-8. doi: 10.1016/j.neulet.2010.06.075. Epub 2010 Jul 3.

The 7th Leonard Berg Symposium, part 2

Strobel G.

J Alzheimers Dis. 2010;20(4):1255-60. doi: 10.3233/JAD-2010-100213.

Ventricular maps in 804 ADNI subjects: correlations with CSF biomarkers and clinical decline

Chou YY, Leporé N, Saharan P, Madsen SK, Hua X, Jack CR, Shaw LM, Trojanowski JQ, Weiner MW, Toga AW, Thompson PM; Alzheimer's Disease Neuroimaging Initiative.

Neurobiol Aging. 2010 Aug;31(8):1386-400. doi: 10.1016/j.neurobiolaging.2010.05.001.

Longitudinal MRI atrophy biomarkers: relationship to conversion in the ADNI cohort

Risacher SL, Shen L, West JD, Kim S, McDonald BC, Beckett LA, Harvey DJ, Jack CR Jr, Weiner MW, Saykin AJ; Alzheimer's Disease Neuroimaging Initiative (ADNI).

Neurobiol Aging. 2010 Aug;31(8):1401-18. doi: 10.1016/j.neurobiolaging.2010.04.029.

Advances and perspectives from genetic research: development of biological markers in Alzheimer's disease

Zetzsche T, Rujescu D, Hardy J, Hampel H.

Expert Rev Mol Diagn. 2010 Jul;10(5):667-90. doi: 10.1586/erm.10.48.

[Alzheimer's disease: immunity and diagnosis]

Herrera-Rivero M, Hernández-Aguilar ME, Manzo J, Aranda-Abreu GE.

Rev Neurol. 2010 Aug;51(3):153-64.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias